Pliant Stock Crashes After Suspension of Idiopathic Pulmonary Fibrosis Study

It is unclear why an independent data safety monitoring board recommended the suspension of Pliant’s Phase IIb/III BEACON-IPF study in idiopathic pulmonary fibrosis.